" class="no-js "lang="en-US"> Protagen Protein Services (PPS) - Medtech Alert
Saturday, August 23, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Protagen Protein Services (PPS) | Pharmtech Focus

Protagen Protein Services (PPS)

About Protagen Protein Services (PPS)

Protagen Protein Services (PPS)

Protagen Protein Services (PPS) is a world leading CRO in protein analytics and its application to GMP-compliant characterization of protein therapeutics. PPS supports multiple Biosimilar developers in achieving and demonstrating Biosimilarity.
Under its PANATecs Brand PPS provides high-grade and innovative Life-Science-Tools for usage in fields of protein analytics, immunology and cell biology.

Related Story

Hero

 Protagen Protein Services Merges with GeneWerk to Integrate Leading Protein and Gene Therapy Analytic Platforms | Pharmtech Focus

Protagen Protein Services Merges with GeneWerk to Integrate Leading Protein and Gene Therapy Analytic Platforms

July 2 2021

Protagen Protein Services (PPS) today announced that it will merge with GeneWerk, an Ampersand portfolio […]